Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treated with adefovir: a 4-year experience.

Liver international : official journal of the International Association for the Study of the Liver - 1 Feb 2011

Chen Chien-Hung, Wang Jing-Houng, Lu Sheng-Nan, Hu Tsung-Hui, Hung Chao-Hung, Chang Min-Hui, Changchien Chi-Sin, Lee Chuan-Mo

Abstract excerpt

BACKGROUND/AIM: We investigated the 4-year incidence and predictors of adefovir resistance in chronic hepatitis B patients with or without lamivudine (LAM)-resistance treated with adefovir dipivoxil with or without short-term LAM overlapping. METHODS: One hundred and two LAM-resistant patients an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cloning, Molecular

Share to Drug Resistance, Viral

Share to Hepatitis B, Chronic

Share to Hepatitis B virus

Share to Lamivudine

Share to Organophosphonates

Source

Identifiers

PMID: 21143368
DOI: 10.1111/j.1478-3231.2010.02416.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-21143368-2026-09-04.1. Manifest publication-graph-cohort-2026-09-04.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treated with adefovir: a 4-year experience.PMID 21143368Read ↗

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.Semantic proximity Read ↗

Virological response to adefovir monotherapy and the risk of adefovir resistance.Semantic proximity Read ↗

Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil.Semantic proximity Read ↗

Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.Semantic proximity Read ↗

Virologic response and resistance to adefovir in patients with chronic hepatitis B.Semantic proximity Read ↗

[Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients].Semantic proximity Read ↗

Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.Semantic proximity Read ↗

Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B.Semantic proximity Read ↗

Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.Semantic proximity Read ↗

Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment.Semantic proximity Read ↗

[Resistance to adefovir in patients with chronic hepatitis B].Semantic proximity Read ↗

Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.